### Coverage Guidelines

Allergy testing and allergy immunotherapy (allergy therapy) are covered when Medicare coverage criteria are met.

#### Allergy Testing

Allergy testing may be covered when Medicare coverage criteria are met.

Refer to the Medicare Claims Processing Manual, Chapter 12, §200 – Allergy Testing and Immunotherapy.

(Accessed November 30, 2021)

Local Coverage Determinations (LCDs)/Local Coverage Articles (LCAs) exist and compliance with these policies is required where applicable. These LCDs/LCAs are available at [https://www.cms.gov/medicare-coverage-database/search.aspx](https://www.cms.gov/medicare-coverage-database/search.aspx)

(Accessed November 30, 2021)

#### Allergen Immunotherapy

Payment may be made for a reasonable supply of antigens that have been prepared for a particular patient if:

- The antigens are prepared by a physician who is a doctor of medicine or osteopathy, and
- The physician who prepared the antigens has examined the patient and has determined a plan of treatment and a dosage regimen.

Antigens must be administered in accordance with the plan of treatment and by a doctor of medicine or osteopathy or by a properly instructed person (who could be the patient) under the supervision of the doctor. The associations of allergists that CMS consulted advised that a reasonable supply of antigens is considered to be not more than a 12-month supply of antigens that has been prepared for a particular patient at any one time. The purpose of the reasonable supply limitation is to assure that the antigens retain their potency and effectiveness over the period in which they are to be administered to the patient. Refer to the Medicare Benefit Policy Manual, Chapter 15, §20.2 – Physician Expense for Allergy Treatment and §50.2 – Determining Self-Administration of Drug or Biological.

- Also refer to the:

(Accessed November 30, 2021)
Local Coverage Determinations (LCDs)/Local Coverage Articles (LCAs) exist and compliance with these policies is required where applicable. These LCDs/LCAs are available at [https://www.cms.gov/medicare-coverage-database/search.aspx](https://www.cms.gov/medicare-coverage-database/search.aspx). (Accessed November 30, 2021)

Allergy Tests/Services

Examples of allergy tests/services include but are not limited to:

- Sublingual antigen; refer to the NCD for Antigens for Sublingual Administration (110.9). (Accessed November 30, 2021)
- Intravenous histamine administration; refer to the NCD for Intravenous Histamines (30.6). (Accessed November 30, 2021)
- Routine Radioallergosorbent Test (RAST) (CPT code 86005 and 86008)
  - Medicare does not have a National Coverage Determination (NCD) for RAST.
  - Local Coverage Determinations (LCDs)/Local Coverage Articles (LCAs) exist for all states/territories and compliance with these policies is required where applicable. For specific LCDs/LCAs, refer to the table for Radioallergosorbent Test (RAST).
- Cytotoxicity testing/Bryan’s test; refer to the NCD for Cytotoxic Food Tests (110.13). (Accessed November 30, 2021)
- Provocative and neutralizing testing (subcutaneous) for food allergies; refer to the NCD for Food Allergy Testing and Treatment (110.11). (Accessed November 30, 2021)
- Sublingual provocative test; refer to the NCD for Food Allergy Testing and Treatment (110.11). (Accessed November 30, 2021)
- Challenge ingestion food testing; refer to the NCD for Challenge Ingestion Food Testing (110.12). (Accessed November 30, 2021)

Supporting Information

**Important Note:** When searching the Medicare Coverage Database, if no LCD/LCA is found, then use the applicable referenced default policy below for coverage guidelines.

<table>
<thead>
<tr>
<th>LCD/LCA ID</th>
<th>LCD/LCA Title</th>
<th>Contractor Type</th>
<th>Contractor Name</th>
<th>Applicable States/Territories</th>
</tr>
</thead>
<tbody>
<tr>
<td>L34063 (A57043)</td>
<td>RAST Type Tests</td>
<td>Part A and B MAC</td>
<td>CGS Administrators, LLC</td>
<td>KY, OH</td>
</tr>
<tr>
<td>L33261 (A57531)</td>
<td>Allergy Testing</td>
<td>Part A and B MAC</td>
<td>First Coast Service Options, Inc.</td>
<td>FL, PR, VI</td>
</tr>
<tr>
<td>L33591 (A56844)</td>
<td>RAST Type Tests</td>
<td>Part A and B MAC</td>
<td>National Government Services, Inc.</td>
<td>CT, IL, MA, ME, MN, NH, NY, RI, VT, WI</td>
</tr>
<tr>
<td>L34313 (A57181)</td>
<td>Allergy Testing</td>
<td>Part A and B MAC</td>
<td>Noridian Healthcare Solutions, LLC</td>
<td>CA, HI, NV, AS, GU, MP</td>
</tr>
<tr>
<td>L36241 (A56558)</td>
<td>Allergy Testing</td>
<td>Part A and B MAC</td>
<td>Novitas Solutions, Inc.</td>
<td>AR, CO, DC, DE, LA, MD, MS, NJ, NM, OK, PA, TX</td>
</tr>
</tbody>
</table>

Note: States notated with an asterisk should follow the other available state-specific
Radioallergosorbent Test (RAST)
Accessed January 3, 2022

<table>
<thead>
<tr>
<th>LCD/LCA ID</th>
<th>LCD/LCA Title</th>
<th>Contractor Type</th>
<th>Contractor Name</th>
<th>Applicable States/Territories</th>
</tr>
</thead>
<tbody>
<tr>
<td>L36402 (A57473)</td>
<td>Allergy Testing</td>
<td>MAC Part B</td>
<td>Wisconsin Physicians Service Insurance Corporation</td>
<td>IA, IN, KS, MI, MO, NE</td>
</tr>
</tbody>
</table>

Back to Guidelines

Policy History/Revision Information

<table>
<thead>
<tr>
<th>Date</th>
<th>Summary of Changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>01/18/2022</td>
<td>● Routine review; no change to coverage guidelines</td>
</tr>
<tr>
<td></td>
<td>● Archived previous policy version MCS003.01</td>
</tr>
</tbody>
</table>

Instructions for Use

This information is being distributed to you for personal reference. The information belongs to UnitedHealthcare and unauthorized copying, use, and distribution are prohibited. This information is intended to serve only as a general reference resource and is not intended to address every aspect of a clinical situation. Physicians and patients should not rely on this information in making health care decisions. Physicians and patients must exercise their independent clinical discretion and judgment in determining care. Each benefit plan contains its own specific provisions for coverage, limitations, and exclusions as stated in the Member’s Evidence of Coverage (EOC)/Summary of Benefits (SB). If there is a discrepancy between this policy and the member’s EOC/SB, the member’s EOC/SB provision will govern. The information contained in this document is believed to be current as of the date noted.

The benefit information in this Coverage Summary is based on existing national coverage policy; however, Local Coverage Determinations (LCDs) may exist and compliance with these policies are required where applicable.

There are instances where this document may direct readers to a UnitedHealthcare Commercial Medical Policy, Medical Benefit Drug Policy, and/or Coverage Determination Guideline (CDG). In the absence of a Medicare National Coverage Determination (NCD), Local Coverage Determination (LCD), or other Medicare coverage guidance, CMS allows a Medicare Advantage Organization (MAO) to create its own coverage determinations, using objective evidence-based rationale relying on authoritative evidence (Medicare IOM Pub. No. 100-16, Ch. 4, §90.5).

CPT® is a registered trademark of the American Medical Association.